Archive for July, 2010

A Step Towards A New Therapy For Chronic Bowel Disease

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs. The NF-kB protein plays a critical role in the inflammatory response and is activated by e.g. TNF, which is produced by the white blood cells.

Read the full story here

Calibra Gains FDA Clearance To Market Finesse(TM) Insulin Patch-Pen For Three-Day Use With Novolog(

Calibra Medical has announced that it has received 510(k) clearance from the FDA to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk’s Novolog® rapid acting insulin. Combining the mealtime therapy-adherence benefits of insulin pumps with the simplicity and affordability of syringes and pens, Calibra’s novel bolus-only patch-pen is a small, adhesively attached, flat device that can be operated discretely through clothing to deliver mealtime, snack time, and correction bolus insulin.

Read the full story here

The Safety Aspect of an X-Ray Technician’s Job

It’s something that most of us have gone through at some point or the other; while we’re initially awed by the size of the machine, we soon realize that having an X-ray taken is a painless procedure that is over in a matter of minutes. What we don’t see however, is the invisible harm caused by the radiation that pours into our bodies in the fraction of a second that we are exposed to the rays. While a few X-rays don’t cause too much damage, there is the possibility of repercussions in the long-term if we undergo the procedure too many times. So this begs the question – how safe are X-ray technicians who are in the vicinity of these machines day in and day out, every day of their working lives?

Yes, X-ray technicians are at risk, but only if they don’t follow the basic safety precautions. In general, if you’re working an X-ray machine all day, here’s what you need to do to stay safe in the both the long and short run:

  • Know the settings of your device and operate them correctly at all times.
  • Understand the acceptable limits of exposure to radiation and act accordingly.
  • Understand the capabilities and limitations of the machine you are working with, whether it is fixed or portable.
  • Since the machine is bulky and requires movement of the heavy arm, ensure that you’re in the right position when making the necessary adjustments. This helps prevent aches and pains and other side effects associated with bad posture.
  • Don’t be careless with activating and deactivating the machine – both patient and your personal safety hinge on this factor since overexposure could lead to dangerous side effects for both.
  • Use the right safety equipment to protect yourself against radiation. Ensure that your safety equipment is in good working condition before you start your job each morning.
  • Check for the viability and preparedness of safety equipment on the machine (warning lights and timers) and those for personal use (shields, lead aprons).
  • If a lead apron is required for a procedure but is not available, move behind a wall or other impenetrable and thick object.
  • Use an electronic personal dosimeter to monitor personal radiation exposure to ensure that you are always within the safe exposure limits.
  • Wear gloves, goggles and/or a mask as and when required.
  • Ensure that your machine is well maintained and clean and sterile so that patients are not affected any more than they already are.

The safety of an X-ray technician lies in their own hands – if they are careless, they end up on the losing side.

By-line:

This guest post is contributed by Kathy Wilson, who writes on the topic of x ray technician school programs . She welcomes your comments at her email id: kathywilson1983@gmail.com

TB4 Improves Neurological Function After Stroke Says Report

RegeneRx Biopharmaceuticals, Inc. has announced that Thymosin beta 4 (TB4), administered to rats after embolic stroke, improved neurological functional outcome compared to control animals. The research was performed under a Material Transfer Agreement between RegeneRx Biopharmaceuticals, Inc. and the Henry Ford Health System. Improvement in neurological function was measured at various time intervals over a seven week period and was statistically significant.

Read the full story here

FDA Accepts BANZEL(R) (Rufinamide) Oral Suspension NDA For Review

Eisai Inc. has announced that the FDA has accepted for review Eisai’s NDA for BANZEL® (rufinamide) Oral Suspension (40 mg/mL). The proposed indication is for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older and adults. The application is based on data from a study designed to demonstrate the bioequivalence of the oral suspension formulation to the currently marketed BANZEL tablet formulation (400 mg).

Read the full story here

Lorcaserin To Get FDA Approval

A new diet pill, Lorcaserin, manufactured by Arena Pharmaceuticals has proven safe and is expected to obtain FDA approval. The now experimental diet pill has proven effective in a two year trial that included nearly 3200 participants. The only noted side effects were headaches and dizziness, according to a study in the New England Journal of Medicine.

Read the full story here.

Mylan Receives FDA Approval For Nabumetone

Mylan Inc. received the FDA approved for its generic version of the osteoarthritis and rheumatoid arthritis drug Nabumetone. The FDA approval allows Mylan to sell 500 milligram and 750 milligram tablets of Nabumetone. It is a nonsteroidal anti-inflammatory drug, which is a popular type of arthritis and inflammation treatment.

Read the full story here.

FDA Approves Daytrana for ADHD

The FDA has approved an expanded age range for a methylphenidate transdermal system (Daytrana; Shire, under license from Noven Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adolescents aged 13 to 17 years. Previously approved for use in children aged 6 to 12 years, the methylphenidate patch is indicated as an integral part of a total treatment program that may include psychological, educational, and social measures.

Roxane Receives FDA Approval For Anastrozole Tablets

Roxane Laboratories has received approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the FDA. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies across the US. Roxane Laboratories’ Anastrozole Tablets are AB rated to ARIMIDEX® (anastrozole) tablets.